Research landscape of glioma and inflammation over the past two decades

过去二十年胶质瘤和炎症的研究概况

阅读:2

Abstract

INTRODUCTION: Glioma is one of the most aggressive brain tumors, and its interaction with inflammation has become an emerging research focus. Despite increasing interest in the role of inflammation in glioma progression and therapy, a comprehensive bibliometric analysis of this field is lacking. METHODS: We conducted a systematic bibliometric analysis of glioma and inflammation research using the Web of Science Core Collection (WoSCC). A total of 4,553 publications from 2005 to 2025 were analyzed for research trends, hotspots, key contributors, and emerging directions using CiteSpace and VOSviewer. RESULTS: Our analysis revealed a significant increase in publications over the past decade. From 2005 to 2025, a total of 4,553 papers related to glioma and inflammation were published. Key contributing countries, institutions, and authors were identified, highlighting the dominance of the U.S. and China in this field. Leading institutions include MD Anderson Cancer Center and Harvard Medical School (USA) and several top Chinese universities. Keyword clustering and co-citation analysis indicated that expression, growth, and survival are major research hotspots. Highly cited papers primarily focused on molecular subtypes, immune modulation, and therapeutic resistance in glioma. ssGSEA analysis revealed that the score based on the 25-gene signature was significantly enriched in GBM and was closely associated with poor prognosis in GBM patients. CONCLUSION: Glioma and inflammation research have gained increasing attention, particularly in tumor immunity and microenvironment studies. This study outlines the current research landscape and trends, potentially serving as a reference for exploring future areas of investigation and collaboration.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。